{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T11:32:38Z","timestamp":1769254358926,"version":"3.49.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>The frequency of food allergies varies between 2% and 10%, depending on characteristics including age, region, race, and method of diagnosis self-reported by patients or oral food challenges (OFCs). The most common allergies reported are tree nuts (1.2%), milk (1.9%), peanuts (2.2%), and shellfish (1.3%). Omalizumab injection has now been approved by the FDA for the treatment of immunoglobulin E-mediated food allergies in specific adults and children aged one year or older. This medication reduces the risk of allergic reactions (Type I), which can include anaphylaxis, when an individual accidentally encounters one or more food allergens. Omalizumab functions by binding to IgE and altering IgE-mediated pathways, which lessens IgE's capacity to cause allergic reactions. Promising outcomes from clinical trials and case studies include lowered anaphylactic risk and enhanced tolerance to allergens. Omalizumab, however, may have adverse effects; thus, close observation is required. Overall, this review sheds light on the efficacy, safety, and clinical implications of omalizumab, highlighting its potential as a useful intervention for IgE-mediated food allergies.<\/jats:p>","DOI":"10.3389\/falgy.2024.1409342","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T05:27:38Z","timestamp":1716874058000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Omalizumab for the reduction of allergic reactions to foods: a narrative review"],"prefix":"10.3389","volume":"5","author":[{"given":"Hafsa","family":"Ghouri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashna","family":"Habib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"Nazir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimerta","family":"Lohana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aymar","family":"Akilimali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2010.10.007","article-title":"Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel","volume":"126","author":"Boyce","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.amjms.2016.11.014","article-title":"Food allergy: what we know now","volume":"353","author":"Moore","year":"2017","journal-title":"Am J Med Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nri.2016.111","article-title":"Food allergy: immune mechanisms, diagnosis and immunotherapy","volume":"16","author":"Yu","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12016-012-8339-6","article-title":"Clinical spectrum of food allergies: a comprehensive review","volume":"46","author":"Ho","year":"2014","journal-title":"Clin Rev Allergy Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.2018-1235","article-title":"The public health impact of parent-reported childhood food allergies in the United States","volume":"142","author":"Gupta","year":"2018","journal-title":"Pediatrics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.jaci.2012.10.017","article-title":"Standardizing double-blind, placebo-controlled oral food challenges: American academy of allergy, asthma & immunology\u2013European academy of allergy and clinical immunology PRACTALL consensus report","volume":"130","author":"Sampson","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/all.13319","article-title":"EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy","volume":"73","author":"Pajno","year":"2018","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/all.13124","article-title":"Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis","volume":"72","author":"Nurmatov","year":"2017","journal-title":"Allergy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2147\/DDDT.S49409","article-title":"Omalizumab, an anti-immunoglobulin E antibody: state of the art","volume":"8","author":"Incorvaia","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/14712598.2018.1438406","article-title":"Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic\/spontaneous urticaria: a systematic review of \u2018real-world\u2019 evidence","volume":"18","author":"Bernstein","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/bjd.13845","article-title":"Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment","volume":"173","author":"Urgert","year":"2015","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials","volume":"137","author":"Zhao","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B13","year":""},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/pai.14057","article-title":"Omalizumab in severe asthma and food allergies with IgE levels >1500\u2005kU\/L: two-year evaluation","volume":"34","author":"Dinardo","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"B15","year":"2024"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aam9171","article-title":"A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders","volume":"9","author":"Wambre","year":"2017","journal-title":"Sci Transl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/639796","article-title":"Prevalence of self-reported food allergy in Lebanon: a middle-eastern taste","volume":"2015","author":"Irani","year":"2015","journal-title":"Int Sch Res Notices"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.rmed.2012.07.010","article-title":"Monitoring free serum IgE in severe asthma patients treated with omalizumab","volume":"106","author":"Korn","year":"2012","journal-title":"Respir Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000237504","article-title":"Serum IgE level drives basophil and mast cell IgE receptor display","volume":"113","author":"MacGlashan","year":"1997","journal-title":"Int Arch Allergy Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fc\u03b5RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovi\u0107","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jaci.2003.11.044","article-title":"Omalizumab rapidly decreases nasal allergic response and Fc\u03b5RI on basophils\u22c6","volume":"113","author":"Lin","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.4049\/jimmunol.179.2.1353","article-title":"Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc\u03b5RI on human skin mast cells","volume":"179","author":"Gomez","year":"2007","journal-title":"The Journal of Immunology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000112504","article-title":"Basophil histamine release decreases during omalizumab therapy in allergic asthmatics","volume":"146","author":"Noga","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jaci.2009.09.012","article-title":"Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge","volume":"125","author":"Eckman","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","article-title":"Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy","volume":"130","author":"Savage","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/j.1365-2125.2011.03962.x","article-title":"Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE","volume":"72","author":"Lowe","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/all.16046","article-title":"A randomized, double-blind placebo-controlled study on the efficacy of omalizumab on food allergy threshold in children with severe food allergy","volume":"79","author":"Mortz","year":"2024","journal-title":"Allergy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/alr.23268","article-title":"Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: a meta-analysis of randomized controlled trials","volume":"14","author":"Zhang","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3390\/jpm12020165","article-title":"Omalizumab: an optimal choice for patients with severe allergic asthma","volume":"12","author":"Kotoulas","year":"2022","journal-title":"J Pers Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jdermsci.2017.03.009","article-title":"Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria","volume":"87","author":"Hide","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/alr.22963","article-title":"Omalizumab and quality of life in nasal polyps: a post hoc analysis","volume":"12","author":"Han","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-label uses of omalizumab","volume":"50","author":"El-Qutob","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/2045-7022-3-29","article-title":"Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells","volume":"3","author":"Chan","year":"2013","journal-title":"Clin Transl Allergy"},{"key":"B38","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/NEJMoa022613","article-title":"Effect of anti-IgE therapy in patients with peanut allergy","volume":"348","author":"Leung","year":"2003","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","article-title":"A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients","volume":"132","author":"Schneider","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/14712598.2021.1904888","article-title":"Biologics in food allergy: up-to-date","volume":"21","author":"Passanisi","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaci.2010.12.1111","article-title":"A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response","volume":"127","author":"Varshney","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1200435","article-title":"Oral immunotherapy for treatment of egg allergy in children","volume":"367","author":"Burks","year":"2012","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"B46","year":""},{"key":"B47","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.5415\/apallergy.2021.11.e27","article-title":"Successful treatment of a patient with adult food allergy and severe asthma using omalizumab","volume":"11","author":"Nishie","year":"2021","journal-title":"Asia Pac Allergy"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00431-011-1540-4","article-title":"Omalizumab in the treatment of eosinophilic esophagitis and food allergy","volume":"170","author":"Rocha","year":"2011","journal-title":"Eur J Pediatr"},{"key":"B49","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.anl.2022.12.001","article-title":"Omalizumab is effective for a patient with pollen-food allergy syndrome who experienced intractable lip edema","volume":"50","author":"Sakamoto","year":"2023","journal-title":"Auris Nasus Larynx"},{"key":"B50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5415\/apallergy.2014.4.4.257","article-title":"Successful management of severe cow\u2019s milk allergy with omalizumab treatment and CD-sens monitoring","volume":"4","author":"Nilsson","year":"2014","journal-title":"Asia Pac Allergy"},{"key":"B51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5414\/ALX02372E","article-title":"Treatment of severe cow\u2019s milk allergy with omalizumab in an adult","volume":"7","author":"Klein","year":"2023","journal-title":"Allergol Select"},{"key":"B52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13223-015-0084-y","article-title":"Successful desensitization in a boy with severe cow\u2019s milk allergy by a combination therapy using omalizumab and rush oral immunotherapy","volume":"11","author":"Takahashi","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B53","first-page":"215","article-title":"A case of severe asthma and peach allergy that improved with omalizumab therapy: a case report","volume":"61","author":"Suzuki","year":"2012","journal-title":"Arerugi"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1409342\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:34:01Z","timestamp":1721385241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1409342\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":53,"alternative-id":["10.3389\/falgy.2024.1409342"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2024.1409342","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"article-number":"1409342"}}